Evolving Standards of Care in Metastatic Prostate Cancer

PROGRAM DESCRIPTION For patients with metastatic prostate cancer (mPRCA), the number of metastases has prognostic and therapeutic implications. Clinicians who treat patients with mPRCA need to recognize patients with oligometastatic ...

PROGRAM DESCRIPTION
For patients with metastatic prostate cancer (mPRCA), the number of metastases has prognostic and therapeutic implications. Clinicians who treat patients with mPRCA need to recognize patients with oligometastatic prostate cancer and be aware that management of patients with fewer than 5 metastases is different from that of patients with polymetastatic disease. Recommendations for the initial management of patients with hormone-naïve polymetastatic disease are also changing. Patients with metastatic castration-resistant prostate cancer have many new treatment options, but clinicians have little guidance on initial selection or sequencing of these agents. This activity will examine evolving best practices in mPRCA.

EDUCATIONAL OBJECTIVES
Upon completion of this educational activity, participants should be able to:Discuss evidence-based approaches to optimizing care for patients with oligometastatic hormone-sensitive prostate cancerDescribe evidence-based management of patients with polymetastatic hormone-sensitive prostate cancerSummarize evidence-based recommendations for the management of patients with metastatic hormone-resistant prostate cancer

---

Write the first review

Resource tags